In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elixir closes financing of equity and debt

Executive Summary

Elixir Pharmaceuticals (therapeutics for metabolic disorders) closed a Series C private placement consisting of $31mm in equity and $15mm in debt. The equity financing was led by MPM Capital with participation from returning shareholders Arch Venture Partners and Oxford Bioscience Partners, and new backers CDIB Bioscience Venture Management, Jafco, and YFY Bioscience. The debt was sold to Hercules Technology Growth Capital. Elixir will use part of the funds for Phase III and regulatory activities for its Type II diabetes drug Glufast; preclinical studies of EX1314 for various metabolic disorders; and preclinical studies for a candidate to treat Type II diabetes and obesity.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Venture Financing

Related Companies